Annual Report

The report records group revenue of USD 3,720 million, up from 2024, and describes the acquisition of Merus as a major step in Genmab’s evolution toward a fully integrated biotech. It reports a 56% reduction in Scope 1 and market-based Scope 2 emissions and 99% renewable electricity across sites. Employee engagement reached 77%, matching the industry benchmark, while the 89% survey participation rate exceeded the 80% benchmark.